Biotech Clinical Laboratories INC

Biotech Clinical Laboratories INC was paid $49.91M by Medicaid between Jan 2018 and Dec 2024, across 235 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 38% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Michigan

Rank by total paid#2 of 108

Median peer was paid$588K

This provider vs. median85×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	142,146	$4.56M
2019	189,678	$7.95M
2020	179,167	$7.53M
2021	270,704	$8.44M
2022	281,298	$7.34M
2023	355,121	$8.90M
2024incomplete	321,413	$5.19M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	38%	159,420	127,634	$18.92M
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	29%	102,555	80,252	$14.70M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	6.2%	45,586	34,850	$3.09M
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	2.0%	26,269	17,079	$981K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.7%	57,640	56,964	$867K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	1.6%	19,909	11,836	$809K
84443	Thyroid stimulating hormone (TSH)	1.5%	83,517	82,360	$753K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	1.4%	8,858	8,003	$694K
80061	Lipid panel	1.3%	87,723	86,610	$626K
80053	Comprehensive metabolic panel	1.2%	101,929	99,701	$617K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	100,870	97,999	$443K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	18,625	18,257	$385K

223 more codes

87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	18,626	$370K
83036	Hemoglobin; glycosylated (A1C)	<1%	69,017	$322K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	20,805	$291K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	3,021	$284K
82607		<1%	31,980	$255K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	5,953	$237K
80074		<1%	8,296	$214K
84439		<1%	42,418	$210K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	11,717	$206K
87536		<1%	3,919	$196K
84403		<1%	12,751	$191K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	<1%	11,535	$185K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	7,724	$165K
84153		<1%	16,242	$158K
82728		<1%	18,165	$130K
87481		<1%	4,340	$128K
86803		<1%	15,385	$117K
84481		<1%	10,321	$101K
86235		<1%	2,454	$98K
87086	Culture, bacterial; quantitative colony count, urine	<1%	20,454	$91K
83970		<1%	3,996	$91K
86769		<1%	3,101	$90K
87522	Neg quan hep c or qual rna	<1%	3,255	$88K
82670		<1%	5,440	$86K
82746		<1%	10,417	$84K
36415	Collection of venous blood by venipuncture	<1%	54,232	$83K
83540		<1%	21,809	$76K
83001		<1%	6,286	$67K
83550		<1%	14,929	$67K
86696		<1%	4,774	$67K
83013		<1%	1,847	$66K
83735		<1%	18,378	$66K
84702		<1%	8,154	$59K
84146		<1%	5,216	$59K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	3,039	$56K
83002		<1%	5,267	$56K
80048	Basic metabolic panel (calcium, ionized)	<1%	11,691	$54K
83880		<1%	2,342	$49K
80076		<1%	13,360	$47K
84100		<1%	18,108	$43K
84144		<1%	3,592	$42K
82043		<1%	13,279	$42K
87088		<1%	8,822	$41K
86038		<1%	5,618	$38K
84480		<1%	4,776	$37K
84550		<1%	15,819	$37K
87340		<1%	6,937	$36K
86780		<1%	4,399	$36K
86695		<1%	3,888	$36K
84460		<1%	12,613	$36K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	156	$35K
86361		<1%	2,677	$35K
84450		<1%	12,493	$35K
88307		<1%	201	$34K
82652		<1%	1,767	$34K
84154		<1%	3,332	$33K
86480		<1%	939	$32K
81001		<1%	19,005	$31K
86481		<1%	548	$31K
87077		<1%	6,267	$30K
82784		<1%	2,469	$30K
86376		<1%	3,434	$29K
87070		<1%	5,440	$29K
87186		<1%	5,808	$29K
86592		<1%	11,133	$27K
85027		<1%	7,433	$26K
82627		<1%	2,099	$26K
82570		<1%	9,523	$26K
84075		<1%	8,519	$23K
86141		<1%	3,147	$22K
87563		<1%	985	$22K
86706		<1%	3,398	$21K
86800		<1%	2,274	$21K
82040		<1%	7,826	$20K
84165		<1%	3,263	$18K
80069		<1%	3,716	$18K
82378		<1%	1,837	$17K
86225		<1%	2,199	$17K
83525		<1%	2,401	$16K
84155		<1%	8,282	$16K
83690		<1%	4,019	$16K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	462	$16K
82533		<1%	1,685	$15K
82247		<1%	5,587	$15K
82550		<1%	4,480	$15K
82947		<1%	6,923	$14K
83020		<1%	1,874	$14K
83521		<1%	932	$14K
86787		<1%	1,765	$13K
82565		<1%	5,204	$13K
82977		<1%	3,265	$12K
86762		<1%	1,636	$12K
86431		<1%	3,541	$11K
86708		<1%	1,501	$11K
83615		<1%	3,668	$11K
80050	General health panel	<1%	5,554	$11K
85652		<1%	7,592	$11K
86334		<1%	993	$11K
82248		<1%	3,576	$11K
85610		<1%	4,771	$11K
84238		<1%	634	$11K
86704		<1%	1,526	$11K
82150		<1%	2,859	$10K
86140		<1%	3,671	$10K
80164		<1%	1,315	$10K
84436		<1%	2,806	$10K
80051		<1%	2,606	$10K
84520		<1%	4,681	$9K
83516		<1%	891	$9K
82105		<1%	1,110	$9K
80055		<1%	326	$8K
86850		<1%	1,499	$8K
81003		<1%	6,656	$8K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	<1%	123	$7K
83090		<1%	690	$7K
86709		<1%	1,173	$6K
85730		<1%	2,367	$6K
86200		<1%	817	$6K
86705		<1%	1,092	$6K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	156	$6K
82785		<1%	594	$5K
81025		<1%	944	$5K
82310		<1%	1,990	$5K
84156		<1%	2,427	$5K
85045		<1%	2,047	$4K
85651		<1%	2,049	$4K
84466		<1%	571	$4K
84311		<1%	1,290	$4K
88112		<1%	214	$4K
87081		<1%	951	$4K
86900		<1%	2,263	$3K
86901		<1%	2,272	$3K
84270		<1%	4,241	$3K
86147		<1%	118	$3K
87581		<1%	155	$3K
86300		<1%	264	$3K
0065U		<1%	1,399	$2K
87625		<1%	130	$2K
80363		<1%	695	$2K
80356		<1%	819	$2K
80365		<1%	860	$2K
80354		<1%	847	$2K
87631		<1%	22	$2K
80347		<1%	730	$2K
99001		<1%	731	$2K
80360		<1%	771	$2K
84484		<1%	276	$2K
82330		<1%	227	$2K
80349		<1%	828	$2K
86304		<1%	176	$2K
83986		<1%	1,158	$2K
83010		<1%	228	$2K
80372		<1%	737	$2K
83992		<1%	763	$2K
80361		<1%	871	$2K
82232		<1%	199	$1K
80359		<1%	757	$1K
84703		<1%	318	$1K
80178		<1%	358	$1K
88142		<1%	127	$1K
86301		<1%	159	$1K
85379		<1%	239	$1K
80348		<1%	870	$1K
80373		<1%	828	$1K
80353		<1%	705	$1K
80355		<1%	543	$1K
86160		<1%	122	$1K
80368		<1%	459	$1K
80369		<1%	430	$994.00
82465		<1%	534	$919.65
80366		<1%	479	$882.00
86255		<1%	113	$797.56
80047		<1%	103	$790.38
85007		<1%	555	$740.79
80358		<1%	866	$725.26
83721		<1%	131	$708.44
84132		<1%	353	$644.82
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	98	$635.08
80367		<1%	381	$610.00
80325		<1%	211	$576.00
87660		<1%	43	$570.99
87480		<1%	43	$567.10
87510		<1%	43	$567.10
G0145	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision	<1%	202	$547.60
G0328	Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous	<1%	55	$527.49
80346		<1%	22	$500.00
86146		<1%	12	$496.09
80345		<1%	470	$483.20
82951		<1%	53	$389.31
84295		<1%	132	$356.21
83014		<1%	83	$312.20
80324		<1%	504	$308.00
86618		<1%	24	$307.09
82668		<1%	25	$278.94
82435		<1%	99	$247.55
86765		<1%	42	$239.95
86665		<1%	15	$238.84
87255		<1%	15	$226.10
85060		<1%	189	$212.48
80362		<1%	22	$200.00
83883		<1%	58	$185.60
80323		<1%	76	$142.80
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	13	$139.68
82374		<1%	44	$123.75
84479		<1%	165	$121.80
80321		<1%	61	$100.00
86777		<1%	13	$90.52
84478		<1%	24	$63.25
80326		<1%	21	$49.00
82950		<1%	13	$36.30
80364		<1%	17	$32.00
81015		<1%	49	$30.74
86593		<1%	12	$30.40
80338		<1%	36	$28.00
80344		<1%	33	$18.00
80337		<1%	31	$15.00
80340		<1%	14	$12.00
80370		<1%	14	$12.00
80371		<1%	13	$10.00
80357		<1%	13	$10.00
80350		<1%	13	$10.00
0210U		0%	86	$0.00
80334		0%	14	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialKHALIFEH, GIOVANNI (VICE PRESIDENT)